Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Idiopathic Parkinson's Disease
Interventions
DRUG

piribedil

Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.

DRUG

pramipexole or ropinirole

continuation of pre-study treatment regimen

Trial Locations (12)

12163

Steglitz

12200

Berlin

13353

Berlin

35043

Marburg

37075

Göttingen

77709

Wolfach

80804

München

89081

Ulm

01307

Dresden

04107

Leipzig

07551

Gera

07646

Stadtroda

Sponsors
All Listed Sponsors
collaborator

FGK Clinical Research GmbH

INDUSTRY

lead

Desitin Arzneimittel GmbH

INDUSTRY